Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
HOUSTON, June 06, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Invited to Present to International BioForum 2018 Conference
HOUSTON, May 24, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center
HOUSTON, May 16, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018
HOUSTON, May 15, 2018 -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial
HOUSTON, May 03, 2018 -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...